Childhood Liver Disease Research Network (ChiLDReN)

Children's Hospital Los Angeles is one of 14 children’s hospitals across the nation designated by the Childhood Liver Disease Research Network (ChiLDReN). ChiLDReN is funded by the National Institutes of Health and represents the continuation of two previous NIH-funded consortia, the Biliary Atresia Research Consortium and the Cholestatic Liver Consortium.

  • Current Research Studies
  • Ongoing Studies
  • Completed Studies

We are currently enrolling infants and children for the following studies (participation is voluntary):

A Prospective Database of Infants with Cholestasis (PROBE)

  • Open to infants less than 180 days of age, diagnosed with cholestasis (blockage of bile flow).

Biliary Atresia Study in Infants and Children (BASIC)

  • Open to infants (older than 6 months of age), children, and young adults and diagnosed with biliary atresia.

Longitudinal Study of Genetic Casues of Intrahepatic Cholestasis (LOGIC)

  • Open to children, adolescents and young adults diagnosed with one of four types of cholestasis (blockage of bile flow): Alagille syndrome, alpha-1 antitrypsin deficiency, progressive familial intrahepatic cholestasis and bile acid synthesis defects.

Longitudinal Study of Mitochondrial Hepatopathies (MITOHEP)

  • Open to infants and children with diagnosed or suspected mitochondrial hepatopathy.

(Closed to new subjects)

  • The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease (ITCH)
  • A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTI), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)
  • Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)
  • A Randomized, Double-blinded, Placebo-controlled Trial of Corticosteroid Therapy Following Portoenterosotomy in Infants with Biliary Atresia (START)
  • A Phase I/IIA Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia (PRIME)

What Our Team Looks Like

Our participation in ChiLDReN represents a multidisciplinary effort that includes:

  • Hepatologists and Gastroenterologists
  • Pediatric surgeons
  • Pathologists
  • Radiologists
  • Geneticists
  • Pulmonologists
  • Research investigators at The Saban Research Institute

Current Funding

Childhood Liver Disease Research Network (ChiLDReN)
2U01DK084538
National Institute of Digestive Disease and Kidney
National Institutes of Health
Principal investigator: Kasper Wang MD

Continuation of the Children’s Hospital LA ChiLDReN Liver Research Center
The major goals of this study are to continue developing the ChiLDReN research center at Children’s Hospital Los Angeles by: 1) enrolling patients with rare congenital liver diseases such as biliary atresia into studies established and conducted by 15 children’s hospitals nationally, 2) conducting network drug trials, 3) studying the role of hepatic progenitor/stem cells in the pathogenesis of biliary atresia, and 4) providing education and outreach to primary care providers, hepatologists and parents.